In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Featured Stories

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

 

Outlook 2023 Leadership

The Busiest Dealmakers Of 2022

With only weeks to go in 2022, the three major pharmas each had inked between 16 and 20 deals. Meanwhile, Pfizer has been less busy with 12 deals, but those include M&A totaling $18.2bn.

Outlook 2023 M & A Deals

Clinical Trials: Have We Finally Reached The New Normal?

Pent-up trial demand during 2020 plus trial modernization strategies yields bumper performance in 2021 as research priorities revert to pre-pandemic trends.

Clinical Trials Outlook 2023 Companies

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Pandemic Drives China Surge In Asia 100 Sales

Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.

Outlook 2023 Companies

RNA Medicines: Advancements Leading To Investments

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Outlook 2023 Growth

Growing Pains: Charting The Rapid Rise Of Chinese IO

Immuno-oncology therapies have revolutionized the treatment of many cancers over the last decade. This period has also witnessed a dramatic growth in China’s domestic pharmaceutical industry, and significant changes in the interaction between this industry and international pharma. This coalescence has led to excitement about the role that Chinese IO could play on the global stage, tempered by regulatory set-backs and revised marketing timelines. 

China ImmunoOncology

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

RNA Medicines: Advancements Leading To Investments

Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.

Outlook 2023 Growth

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Commercial India

Pharma’s Digital Pathology Build-Out; Part 2 – What It Means

Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.

Diagnostics Artificial Intelligence
Data Spotlight

Financing Quarterly Statistics, Q2 2022

During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Outlook 2023 C-Suite Speaks

Lessons From Novo Nordisk’s Mads Øvlisen, The Father Of CSR

When Mads Øvlisen was persuaded by his father-in-law to join the family business, Novo Industri, in 1974 for a short stint in the legal department, little did he know it would the beginning of a lifetime of service to the company that he helped to shape into the diabetes powerhouse it is today.

Outlook 2023 Leadership

Syngene COO On Delivering Cost Gains For mRNA Products

Syngene’s COO, Mahesh Bhalgat, said the firm is better placed than some peers to serve clients for biologics-based advanced therapies and address the cost element for new modalities like mRNA. He also outlines the research, development and manufacturing services company's capabilities in oligonucleotide-based therapeutics, an area that's seeing growing interest.

Commercial India

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

2023: A Bumpy Road Ahead For Implementation of Medtech Regulations

Originally intended to increase medical device safety, the EU’s medtech regulation is so hampered in its implementation that it is now arguably a bigger potential threat to patients than any of the scandals leading to its more stringent requirements.

Outlook 2023 Medical Device

Flight Of The Navigator: Bluebird bio's Andrew Obenshain

For 12 years, bluebird bio has been developing gene therapies for rare genetic disease and now, with two approvals under its belt, the company is continuing to explore uncharted territory as it brings forward innovative new treatments. Holding the map is CEO Andrew Obenshain.

Outlook 2023 C-Suite Speaks

Humira Biosimilars Prepare For US Competition In 2023

The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.

Outlook 2023 United States

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

2023: A Bumpy Road Ahead For Implementation of Medtech Regulations

Originally intended to increase medical device safety, the EU’s medtech regulation is so hampered in its implementation that it is now arguably a bigger potential threat to patients than any of the scandals leading to its more stringent requirements.

Outlook 2023 Medical Device

Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative

From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.

Outlook 2023 Clinical Trials

Snapshot: November Highlights

A selection of articles you might have missed from November 2022, during which In Vivo shone the spotlight on the Asia Pacific region.

BioPharmaceutical Strategy
UsernamePublicRestriction

Register